organ growth redempt
setup pt
post solid organ growth improv
quell linger concern around health underli busi
overal growth improv cc includ vsi urolift
growth benefit higher util look ahead combo
legaci urolift vsi eventu pipelin repla manta
capabl sustain hsd top-lin ep next year
organ growth surg hsd look sustain legaci growth
improv ex neotract last
revers part driven catch slip distributor order last
ad growth bigger driver came rebound volum
vascular na surgic na
urolift hyper-growth get start due time neotract hyper-
growth continu urolift contribut versu
strong perform light manufacturing/suppli constraint extend
sept suppli normal growth come mostli util exist
center also expans new site co urologist
train us last although perform help better
econom physician bigger driver appear outcom low ed revers
urinari retent catheter data along grow real world evid
center add rise util support urolift reach mark overtim
pipelin look increasingli attract sever product capabl ad
growth contribut inclus percuv receiv
clearanc repla manta acquir essenti medic top-lin see
benefit percuv manta latter eu sale follow
substanti contribut beyond
shift rais pt buy solid setup goe
prior reflect still hsd organ growth revis
prior off-set sell day fx pt goe prior
continu assign premium multipl revis ep estim importantli
combo urolift vsi pipelin give increas line sight ep
time-frame upsid follow-on
gener earn estim reflect cash ep
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
buy thesi predic best-in-class report
organ top-lin growth profil rel peer
continu upsid adjust om restructur
balanc sheet flexibl support continu tuck-
 activ
posit one better posit
mid-cap hospit suppli provid compani
increasingli attract larger diversifi med-tech peer
deep-div analys vasc neotract acquisit
along detail bottom-up analysi exist
integr vascular solut
success bla trial repla
on-going launch percuv
aua meet may
mid-singl digit organ growth annual
signific neotract revenu contribut
pipelin product repla remain schedul
limit contribut percuv earli launch
high-singl digit organ growth annual op
neotract revenu exceed trajectori mileston
beyond expect contribut repla success trial
beyond contribut percuv earli launch
accret
low-singl digit organ growth annual
neotract revenu contribut minim
delay product pipelin process repla
percuv launch take longer expect adopt
dilut deal execut prior
page
pleas see import disclosur inform page report
page
pleas see import disclosur inform page report
